hat
CYTOMEL gen yon aparisyon rapid nan aksyon ak efè rezidyèl nan preparasyon an lòt tiwoyid pouvwa pèsiste pou premye semèn yo plizyè apre kòmanse terapi CYTOMEL. Lè ou chanje yon pasyan nan CYTOMEL, sispann terapi levotiroksin epi kòmanse CYTOMEL nan yon dòz ki ba. Piti piti ogmante dòz la CYTOMEL selon repons pasyan an.
eng
CYTOMEL has a rapid onset of action and residual effects of the other thyroid preparation may persist for the first several weeks after initiating CYTOMEL therapy. When switching a patient to CYTOMEL, discontinue levothyroxine therapy and initiate CYTOMEL at a low dosage. Gradually increase the CYTOMEL dose according to the patient’s response.